Review



amoydx super-arms® egfr mutation test kit  (Amoy Diagnostics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Amoy Diagnostics amoydx super-arms® egfr mutation test kit
    Schematic diagram of the study design. Paired baseline blood and tumor tissue samples were obtained from each patient. The neoadjuvant treatment regimen was assigned based on <t>EGFR</t> mutation status. After the completion of neoadjuvant treatment, pre-surgical evaluation was conducted. Paired blood and tumor tissue samples were obtained from patients who underwent surgery. Post-surgery evaluations were conducted every 3 months. Abbreviations: NSCLC, non-small cell lung cancer; N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ARMS-PCR, amplification refractory mutation polymerase chain reaction; EGFR −, wild-type EGFR ; EGFR +, EGFR mutant; EGFR-TKI, EGFR tyrosine kinase inhibitor; EBUS, endobronchial ultrasonography; CT-scan, computed tomography scan; RECIST, Response Evaluation Criteria in Solid Tumors.
    Amoydx Super Arms® Egfr Mutation Test Kit, supplied by Amoy Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amoydx+egfr+mutation+test+kit/amoydx+egfr+gene+mutation+detection+kit/pmc07607055-82-34-40
    Average 90 stars, based on 1 article reviews
    amoydx super-arms® egfr mutation test kit - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients"

    Article Title: Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

    Journal: The Journal of International Medical Research

    doi: 10.1177/0300060519887275

    Schematic diagram of the study design. Paired baseline blood and tumor tissue samples were obtained from each patient. The neoadjuvant treatment regimen was assigned based on EGFR mutation status. After the completion of neoadjuvant treatment, pre-surgical evaluation was conducted. Paired blood and tumor tissue samples were obtained from patients who underwent surgery. Post-surgery evaluations were conducted every 3 months. Abbreviations: NSCLC, non-small cell lung cancer; N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ARMS-PCR, amplification refractory mutation polymerase chain reaction; EGFR −, wild-type EGFR ; EGFR +, EGFR mutant; EGFR-TKI, EGFR tyrosine kinase inhibitor; EBUS, endobronchial ultrasonography; CT-scan, computed tomography scan; RECIST, Response Evaluation Criteria in Solid Tumors.
    Figure Legend Snippet: Schematic diagram of the study design. Paired baseline blood and tumor tissue samples were obtained from each patient. The neoadjuvant treatment regimen was assigned based on EGFR mutation status. After the completion of neoadjuvant treatment, pre-surgical evaluation was conducted. Paired blood and tumor tissue samples were obtained from patients who underwent surgery. Post-surgery evaluations were conducted every 3 months. Abbreviations: NSCLC, non-small cell lung cancer; N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ARMS-PCR, amplification refractory mutation polymerase chain reaction; EGFR −, wild-type EGFR ; EGFR +, EGFR mutant; EGFR-TKI, EGFR tyrosine kinase inhibitor; EBUS, endobronchial ultrasonography; CT-scan, computed tomography scan; RECIST, Response Evaluation Criteria in Solid Tumors.

    Techniques Used: Mutagenesis, Amplification, Polymerase Chain Reaction, Computed Tomography

    Demographic characteristics according to neoadjuvant regimen.
    Figure Legend Snippet: Demographic characteristics according to neoadjuvant regimen.

    Techniques Used: Mutagenesis, Biomarker Discovery

    Clinical responses to neoadjuvant treatment. (a). EGFR-TKI neoadjuvant therapy provides better clinical responses compared with chemotherapy. Post-neoadjuvant therapy objective response rate (ORR) for N-chemo and N-TKI groups. Cyan represents the number of patients with SD. Blue represents the number of patients who achieved PR. Orange represents patients whose best response was evaluated as PD. (b)–(c). EGFR-TKI neoadjuvant therapy significantly reduces tumor diameter. (b). Average tumor diameter for patients in each treatment regimen. (c). Average changes in tumor diameter. p -values were calculated using a t-test. (d). EGFR-TKI neoadjuvant therapy significantly reduces maximum allele fraction (maxAF). MaxAF detected in tumor biopsy samples at baseline and surgically resected tumor specimens post-neoadjuvant therapy in the N-chemo and N-TKI groups. Absolute levels of maxAF. A t-test was used to calculate statistical significance. (e)–(f). Serum carcinoembryonic antigen (CEA) levels were significantly reduced in patients who received neoadjuvant EGFR-TKI therapy. (e). Absolute serum CEA levels (ng/ml). F. Ratio of serum CEA after neoadjuvant therapy relative to baseline. Abbreviations: N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ORR, overall objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CEA, carcinoembryonic antigen.
    Figure Legend Snippet: Clinical responses to neoadjuvant treatment. (a). EGFR-TKI neoadjuvant therapy provides better clinical responses compared with chemotherapy. Post-neoadjuvant therapy objective response rate (ORR) for N-chemo and N-TKI groups. Cyan represents the number of patients with SD. Blue represents the number of patients who achieved PR. Orange represents patients whose best response was evaluated as PD. (b)–(c). EGFR-TKI neoadjuvant therapy significantly reduces tumor diameter. (b). Average tumor diameter for patients in each treatment regimen. (c). Average changes in tumor diameter. p -values were calculated using a t-test. (d). EGFR-TKI neoadjuvant therapy significantly reduces maximum allele fraction (maxAF). MaxAF detected in tumor biopsy samples at baseline and surgically resected tumor specimens post-neoadjuvant therapy in the N-chemo and N-TKI groups. Absolute levels of maxAF. A t-test was used to calculate statistical significance. (e)–(f). Serum carcinoembryonic antigen (CEA) levels were significantly reduced in patients who received neoadjuvant EGFR-TKI therapy. (e). Absolute serum CEA levels (ng/ml). F. Ratio of serum CEA after neoadjuvant therapy relative to baseline. Abbreviations: N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ORR, overall objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CEA, carcinoembryonic antigen.

    Techniques Used:

    Kaplan–Meier estimation of the survival of neoadjuvant-treated patients. (a)–(c). Analysis of progression-free survival (PFS) (a), disease-free survival (DFS) (b), and overall survival (OS) (c) for resected, neoadjuvant chemotherapy, and erlotinib-treated patients. (d)–(e). Analyses of recurrence-free survival (RFS) (d) and overall survival (OS) (e) in chemotherapy-treated patients with or without subsequent surgery. Abbreviations: N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); DFS, disease-free survival; OS, overall survival; RFS, recurrence-free survival.
    Figure Legend Snippet: Kaplan–Meier estimation of the survival of neoadjuvant-treated patients. (a)–(c). Analysis of progression-free survival (PFS) (a), disease-free survival (DFS) (b), and overall survival (OS) (c) for resected, neoadjuvant chemotherapy, and erlotinib-treated patients. (d)–(e). Analyses of recurrence-free survival (RFS) (d) and overall survival (OS) (e) in chemotherapy-treated patients with or without subsequent surgery. Abbreviations: N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); DFS, disease-free survival; OS, overall survival; RFS, recurrence-free survival.

    Techniques Used:

    Related Articles

    Mutagenesis:

    Article Title: Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion
    Article Snippet: DNA extraction and EGFR mutation detection DNA from paraffin-embedded tissue sections and cell blocks (carcinoma cytology specimens) was extracted by AmoyDx DNA FFPE tissue kit (Amoy Diagnostics Co., Ltd., Xiamen, China). .. AmoyDx EGFR mutation test kit (Amoy Diagnostics Co., Ltd., Xiamen, China) was used to detect 29 EGFR mutation hotspots in exon 18-21. .. DNA samples were amplified by Real Time PCR (Agilent Stratagene Mx3000P).

    Article Title: Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance
    Article Snippet: .. Molecular results were confirmed using the AmoyDx EGFR Mutation Test kit (Amoy Diagnostics Co. Ltd., Xiamen, China) for the detection of somatic mutations in the EGFR gene, using the principle of amplified refractory mutation. .. The assay was performed according to the manufacturer's instructions, using the Applied Biosystems StepOnePlusTM Real-Time PCR system (Thermo Fisher Scientific, Inc.; ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 2. caption a7 Magnitude of normalized fluorescence signal generated by the reporter at each cycle during polymerase chain reaction amplification of the histological sample from the metastatic supraclavicular lymph node.

    Article Title: Gefitinib maintenance therapy in Chinese advanced-stage lung adenocarcinoma patients with EGFR mutations treated with prior chemotherapy.
    Article Snippet: .. The presence of EGFR mutations was detected using the AmoyDx EGFR mutation Test Kit (Amoy Diagnostics) that can detect 29 mutations in the EGFR gene including an exon 19 deletion, 21L858R, 18G719X, 20S768I, exon 20 insertion, 20T790m, and 21L861Q. ..

    Amplification:

    Article Title: Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance
    Article Snippet: .. Molecular results were confirmed using the AmoyDx EGFR Mutation Test kit (Amoy Diagnostics Co. Ltd., Xiamen, China) for the detection of somatic mutations in the EGFR gene, using the principle of amplified refractory mutation. .. The assay was performed according to the manufacturer's instructions, using the Applied Biosystems StepOnePlusTM Real-Time PCR system (Thermo Fisher Scientific, Inc.; ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 2. caption a7 Magnitude of normalized fluorescence signal generated by the reporter at each cycle during polymerase chain reaction amplification of the histological sample from the metastatic supraclavicular lymph node.



    Similar Products

    amoydx super-arms® egfr mutation test kit  (Amoy Diagnostics)
    90
    Amoy Diagnostics amoydx super-arms® egfr mutation test kit
    Schematic diagram of the study design. Paired baseline blood and tumor tissue samples were obtained from each patient. The neoadjuvant treatment regimen was assigned based on <t>EGFR</t> mutation status. After the completion of neoadjuvant treatment, pre-surgical evaluation was conducted. Paired blood and tumor tissue samples were obtained from patients who underwent surgery. Post-surgery evaluations were conducted every 3 months. Abbreviations: NSCLC, non-small cell lung cancer; N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ARMS-PCR, amplification refractory mutation polymerase chain reaction; EGFR −, wild-type EGFR ; EGFR +, EGFR mutant; EGFR-TKI, EGFR tyrosine kinase inhibitor; EBUS, endobronchial ultrasonography; CT-scan, computed tomography scan; RECIST, Response Evaluation Criteria in Solid Tumors.
    Amoydx Super Arms® Egfr Mutation Test Kit, supplied by Amoy Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amoydx+egfr+mutation+test+kit/amoydx+egfr+gene+mutation+detection+kit/pmc07607055-82-34-40
    Average 90 stars, based on 1 article reviews
    amoydx super-arms® egfr mutation test kit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    amoydx egfr mutation test kit  (Amoy Diagnostics)
    90
    Amoy Diagnostics amoydx egfr mutation test kit
    <t> EGFR </t> mutations in never-smoking female lung adenocarcinoma patients with MPE or biopsy samples
    Amoydx Egfr Mutation Test Kit, supplied by Amoy Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amoydx+egfr+mutation+test+kit/amoydx+egfr+gene+mutation+detection+kit/pmc06958231-50-0-5
    Average 90 stars, based on 1 article reviews
    amoydx egfr mutation test kit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    real-time pcr-based amoydx® egfr t790m mutation test kit  (Amoy Diagnostics)
    90
    Amoy Diagnostics real-time pcr-based amoydx® egfr t790m mutation test kit
    <t> EGFR </t> mutations in never-smoking female lung adenocarcinoma patients with MPE or biopsy samples
    Real Time Pcr Based Amoydx® Egfr T790m Mutation Test Kit, supplied by Amoy Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amoydx+egfr+mutation+test+kit/adx+egfr+mutations+detection+kit/10__1007_slash_s00292___017___0295___8-632-16-22
    Average 90 stars, based on 1 article reviews
    real-time pcr-based amoydx® egfr t790m mutation test kit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Schematic diagram of the study design. Paired baseline blood and tumor tissue samples were obtained from each patient. The neoadjuvant treatment regimen was assigned based on EGFR mutation status. After the completion of neoadjuvant treatment, pre-surgical evaluation was conducted. Paired blood and tumor tissue samples were obtained from patients who underwent surgery. Post-surgery evaluations were conducted every 3 months. Abbreviations: NSCLC, non-small cell lung cancer; N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ARMS-PCR, amplification refractory mutation polymerase chain reaction; EGFR −, wild-type EGFR ; EGFR +, EGFR mutant; EGFR-TKI, EGFR tyrosine kinase inhibitor; EBUS, endobronchial ultrasonography; CT-scan, computed tomography scan; RECIST, Response Evaluation Criteria in Solid Tumors.

    Journal: The Journal of International Medical Research

    Article Title: Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

    doi: 10.1177/0300060519887275

    Figure Lengend Snippet: Schematic diagram of the study design. Paired baseline blood and tumor tissue samples were obtained from each patient. The neoadjuvant treatment regimen was assigned based on EGFR mutation status. After the completion of neoadjuvant treatment, pre-surgical evaluation was conducted. Paired blood and tumor tissue samples were obtained from patients who underwent surgery. Post-surgery evaluations were conducted every 3 months. Abbreviations: NSCLC, non-small cell lung cancer; N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ARMS-PCR, amplification refractory mutation polymerase chain reaction; EGFR −, wild-type EGFR ; EGFR +, EGFR mutant; EGFR-TKI, EGFR tyrosine kinase inhibitor; EBUS, endobronchial ultrasonography; CT-scan, computed tomography scan; RECIST, Response Evaluation Criteria in Solid Tumors.

    Article Snippet: Tissue DNA was used to assess the common EGFR mutations in exon 21 L858R and exon 19 deletions (19del) by direct sequencing and amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) methods, respectively, using an AmoyDx Super-ARMS® EGFR mutation test kit (Amoy Diagnostics, Xiamen, China).

    Techniques: Mutagenesis, Amplification, Polymerase Chain Reaction, Computed Tomography

    Demographic characteristics according to neoadjuvant regimen.

    Journal: The Journal of International Medical Research

    Article Title: Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

    doi: 10.1177/0300060519887275

    Figure Lengend Snippet: Demographic characteristics according to neoadjuvant regimen.

    Article Snippet: Tissue DNA was used to assess the common EGFR mutations in exon 21 L858R and exon 19 deletions (19del) by direct sequencing and amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) methods, respectively, using an AmoyDx Super-ARMS® EGFR mutation test kit (Amoy Diagnostics, Xiamen, China).

    Techniques: Mutagenesis, Biomarker Discovery

    Clinical responses to neoadjuvant treatment. (a). EGFR-TKI neoadjuvant therapy provides better clinical responses compared with chemotherapy. Post-neoadjuvant therapy objective response rate (ORR) for N-chemo and N-TKI groups. Cyan represents the number of patients with SD. Blue represents the number of patients who achieved PR. Orange represents patients whose best response was evaluated as PD. (b)–(c). EGFR-TKI neoadjuvant therapy significantly reduces tumor diameter. (b). Average tumor diameter for patients in each treatment regimen. (c). Average changes in tumor diameter. p -values were calculated using a t-test. (d). EGFR-TKI neoadjuvant therapy significantly reduces maximum allele fraction (maxAF). MaxAF detected in tumor biopsy samples at baseline and surgically resected tumor specimens post-neoadjuvant therapy in the N-chemo and N-TKI groups. Absolute levels of maxAF. A t-test was used to calculate statistical significance. (e)–(f). Serum carcinoembryonic antigen (CEA) levels were significantly reduced in patients who received neoadjuvant EGFR-TKI therapy. (e). Absolute serum CEA levels (ng/ml). F. Ratio of serum CEA after neoadjuvant therapy relative to baseline. Abbreviations: N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ORR, overall objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CEA, carcinoembryonic antigen.

    Journal: The Journal of International Medical Research

    Article Title: Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

    doi: 10.1177/0300060519887275

    Figure Lengend Snippet: Clinical responses to neoadjuvant treatment. (a). EGFR-TKI neoadjuvant therapy provides better clinical responses compared with chemotherapy. Post-neoadjuvant therapy objective response rate (ORR) for N-chemo and N-TKI groups. Cyan represents the number of patients with SD. Blue represents the number of patients who achieved PR. Orange represents patients whose best response was evaluated as PD. (b)–(c). EGFR-TKI neoadjuvant therapy significantly reduces tumor diameter. (b). Average tumor diameter for patients in each treatment regimen. (c). Average changes in tumor diameter. p -values were calculated using a t-test. (d). EGFR-TKI neoadjuvant therapy significantly reduces maximum allele fraction (maxAF). MaxAF detected in tumor biopsy samples at baseline and surgically resected tumor specimens post-neoadjuvant therapy in the N-chemo and N-TKI groups. Absolute levels of maxAF. A t-test was used to calculate statistical significance. (e)–(f). Serum carcinoembryonic antigen (CEA) levels were significantly reduced in patients who received neoadjuvant EGFR-TKI therapy. (e). Absolute serum CEA levels (ng/ml). F. Ratio of serum CEA after neoadjuvant therapy relative to baseline. Abbreviations: N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); ORR, overall objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CEA, carcinoembryonic antigen.

    Article Snippet: Tissue DNA was used to assess the common EGFR mutations in exon 21 L858R and exon 19 deletions (19del) by direct sequencing and amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) methods, respectively, using an AmoyDx Super-ARMS® EGFR mutation test kit (Amoy Diagnostics, Xiamen, China).

    Techniques:

    Kaplan–Meier estimation of the survival of neoadjuvant-treated patients. (a)–(c). Analysis of progression-free survival (PFS) (a), disease-free survival (DFS) (b), and overall survival (OS) (c) for resected, neoadjuvant chemotherapy, and erlotinib-treated patients. (d)–(e). Analyses of recurrence-free survival (RFS) (d) and overall survival (OS) (e) in chemotherapy-treated patients with or without subsequent surgery. Abbreviations: N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); DFS, disease-free survival; OS, overall survival; RFS, recurrence-free survival.

    Journal: The Journal of International Medical Research

    Article Title: Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

    doi: 10.1177/0300060519887275

    Figure Lengend Snippet: Kaplan–Meier estimation of the survival of neoadjuvant-treated patients. (a)–(c). Analysis of progression-free survival (PFS) (a), disease-free survival (DFS) (b), and overall survival (OS) (c) for resected, neoadjuvant chemotherapy, and erlotinib-treated patients. (d)–(e). Analyses of recurrence-free survival (RFS) (d) and overall survival (OS) (e) in chemotherapy-treated patients with or without subsequent surgery. Abbreviations: N-chemo, neoadjuvant chemotherapy group; N-TKI, neoadjuvant EGFR-tyrosine kinase inhibitor (TKI); DFS, disease-free survival; OS, overall survival; RFS, recurrence-free survival.

    Article Snippet: Tissue DNA was used to assess the common EGFR mutations in exon 21 L858R and exon 19 deletions (19del) by direct sequencing and amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) methods, respectively, using an AmoyDx Super-ARMS® EGFR mutation test kit (Amoy Diagnostics, Xiamen, China).

    Techniques:

    EGFR mutations in never-smoking female lung adenocarcinoma patients with MPE or biopsy samples

    Journal: International Journal of Clinical and Experimental Pathology

    Article Title: Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion

    doi:

    Figure Lengend Snippet: EGFR mutations in never-smoking female lung adenocarcinoma patients with MPE or biopsy samples

    Article Snippet: AmoyDx EGFR mutation test kit (Amoy Diagnostics Co., Ltd., Xiamen, China) was used to detect 29 EGFR mutation hotspots in exon 18-21.

    Techniques:

    EGFR mutation in two age groups in all patients

    Journal: International Journal of Clinical and Experimental Pathology

    Article Title: Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion

    doi:

    Figure Lengend Snippet: EGFR mutation in two age groups in all patients

    Article Snippet: AmoyDx EGFR mutation test kit (Amoy Diagnostics Co., Ltd., Xiamen, China) was used to detect 29 EGFR mutation hotspots in exon 18-21.

    Techniques: Mutagenesis

    EGFR mutation in two age groups in patients with biopsy samples

    Journal: International Journal of Clinical and Experimental Pathology

    Article Title: Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion

    doi:

    Figure Lengend Snippet: EGFR mutation in two age groups in patients with biopsy samples

    Article Snippet: AmoyDx EGFR mutation test kit (Amoy Diagnostics Co., Ltd., Xiamen, China) was used to detect 29 EGFR mutation hotspots in exon 18-21.

    Techniques: Mutagenesis

    EGFR mutation in two age groups in patients with MPE

    Journal: International Journal of Clinical and Experimental Pathology

    Article Title: Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion

    doi:

    Figure Lengend Snippet: EGFR mutation in two age groups in patients with MPE

    Article Snippet: AmoyDx EGFR mutation test kit (Amoy Diagnostics Co., Ltd., Xiamen, China) was used to detect 29 EGFR mutation hotspots in exon 18-21.

    Techniques: Mutagenesis

    EGFR mutations in different age segments in patients with biopsy samples (P=0.29). Number of patients with EGFR mutations/number of total patients in each group. Mt: mutation.

    Journal: International Journal of Clinical and Experimental Pathology

    Article Title: Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion

    doi:

    Figure Lengend Snippet: EGFR mutations in different age segments in patients with biopsy samples (P=0.29). Number of patients with EGFR mutations/number of total patients in each group. Mt: mutation.

    Article Snippet: AmoyDx EGFR mutation test kit (Amoy Diagnostics Co., Ltd., Xiamen, China) was used to detect 29 EGFR mutation hotspots in exon 18-21.

    Techniques: Mutagenesis

    EGFR mutations in different age segments in patients with malignant pleural effusion (P=0.04). Number of patients with EGFR mutations/number of total patients in each group. Mt: mutation.

    Journal: International Journal of Clinical and Experimental Pathology

    Article Title: Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion

    doi:

    Figure Lengend Snippet: EGFR mutations in different age segments in patients with malignant pleural effusion (P=0.04). Number of patients with EGFR mutations/number of total patients in each group. Mt: mutation.

    Article Snippet: AmoyDx EGFR mutation test kit (Amoy Diagnostics Co., Ltd., Xiamen, China) was used to detect 29 EGFR mutation hotspots in exon 18-21.

    Techniques: Mutagenesis